Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.Delinia
(Acq 2017)Receptos
(Acq 2015)Quanticel
(Acq 2015)Avila Therapeutics, Inc
(Acq 2012)Abraxis BioScience Inc
(Acq 2010)Gloucester Pharmaceuticals
(Acq 2009)Pharmion Corporation
(Acq 2008)Anthrogenesis
(Acq 2002)Signal Pharmaceuticals, Inc
(Acq 2000)Celgene
(Spun off from
Celanese in 1986)
Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.
